The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mesoblast (MSB) has submitted its Biologics Licence Application (BLA) to the U.S. Food and Drug Administration (US FDA) for Ryoncil
  • Ryoncil is the company’s lead cell therapy used to treat children with steroid-refractory acute graft versus host disease
  • Mesoblast requested the application be given Priority Review as there currently isn’t any FDA-approved treatments for children with this disease
  • If this goes well, Ryoncil is expected to be launched in the U.S. some time this year
  • Mesoblast is down a slight 0.67 per cent with shares trading at $2.98 each

Mesoblast (MSB) has submitted its Biologics Licence Application (BLA) to the United States Food and Drug Administration (US FDA) for Ryoncil.

Ryoncil (remestemcel-L) is Mesoblast’s lead allogeneic cell therapy which is used to treat children with steroid-refractory acute graft versus host disease (SR-aGVHD).

The regenerative medicine company filed the final module for the application with the FDA on January 31. It has requested Priority Review of the BLA by the FDA and, if approved, Ryoncil is expected to be launched in the U.S. this year.

“This is a major corporate milestone for Mesoblast,” CEO Dr Silviu Itescu said.

Acute GVHD occurs in about 50 per cent of patients who go through an allogenic bone marrow transplant.

In patients with the most severe form of the disease, mortality is as high as 90 per cent. Unfortunately however, there isn’t any FDA-approved treatments in the U.S. for children with SR-aGVHD.

Ryoncil has been used on 309 children with SR-aGVHD across three separate studies. It was used as a salvage therapy in an expanded access program in 241 children who failed institutional standard of care.

The lead drug candidate was also used as first-line therapy in Mesoblast’s Phase 3 trial in 55 children with SR-aGVHD, 89 per cent of whom has a severe form of the disease.

“We look forward to working closely with the FDA to potentially bring Ryoncil to market and providing our innovative biologic therapy to the many children with this life-threatening condition,” Dr Silviu added.

Mesoblast is down a slight 0.67 per cent with shares trading at $2.98 each at 12:11 pm AEDT.

MSB by the numbers
More From The Market Online
Disability NDIS concept

Freedom Care Group reveals NDIS wants to ban it providing program services

Shares in Freedom Care Group (ASX:FCG) were down more than -3% on Wednesday after revealing the…
Image representing bacterial infections in the immune system

Recce reaches key dosing milestone in testing of skin infection gel

Recce Pharmaceuticals Ltd has successfully dosed 20 out of 30 participants in its Phase II trial…
Bank of England London town

Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health…
DNA RNA therapy concept

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11,…